CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The Commonwealth Neuroendocrine Tumour (CommNETs) Research Collaborative held their annual research workshop on November 12th and 13th in Christchurch New Zealand. With close to 60 people in attendance and at least 20 research projects to complete and develop, the 2023 CommNETs Annual Research Workshop was certainly productive and successful.
San Antonio Breast Cancer Symposium (SABCS) takes place this year at the Henry B. Gonzalez Convention Centre, December 5-9, 2023. SABCS is an International scientific symposium for scientists and clinicians in breast cancer. The event is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.
CCTG will be presenting the following at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. ASH is the world's largest professional gathering of both clinicians and scientists around the world who are working to conquer blood diseases.
CCTG SC.26: Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia
